Navigation Links
Gleevec Prevents Return of Intestinal Cancer, Study Confirms
Date:3/19/2009

Drug is shown to be most effective on larger tumors

THURSDAY, March 19 (HealthDay News) -- Taking Gleevec after surgery to remove a gastrointestinal stromal tumor improves tumor-free survival, a U.S. study has confirmed.

Gastrointestinal stromal tumors (GIST), the most common soft-tissue cancer of the intestinal tract, typically occur in the stomach or small intestine. About 3,000 to 4,000 cases are diagnosed in the United States each year. According to background information in the study, about 85 percent of these tumors have a protein that allows them to be inhibited by Gleevec, known as imatinib.

The finding stems from a phase 3 trial for the drug, which was approved last year by the U.S. Food and Drug Administration to treat people who've had surgery to remove a GIST. The drug already was approved for treating certain types of adult leukemia.

The trial included more than 700 people with a GIST at least 3 centimeters in size that tested positive for the protein. The participants were randomly selected to take either 400 milligrams of Gleevec or a placebo once a day for a year after surgery to remove their tumor.

After a median follow-up of almost 20 months, 8 percent of people in the Gleevec group and 20 percent of those in the placebo group had experienced tumor recurrence or had died. After a year, recurrence-free survival was 98 percent for those taking the drug and 83 percent for people taking the placebo.

Tumor size affected treatment success, the study found. Gleevec had the most effect on tumors that were 10 cm or larger, less effect on tumors between 6 and 10 cm, and the least effect on tumors between 3 and 6 cm, the study reported.

The most common serious side effects experienced by people taking the drug were dermatitis, abdominal pain and diarrhea.

Dr. Ronald DeMatteo, of Memorial Sloan-Kettering Cancer Center, and his fellow researchers said that their "findings will affect the management of patients with primary gastrointestinal stromal tumor and could have relevance to the adjuvant use of other molecular agents for cancer."

The study appears online and in an upcoming print issue of The Lancet.

Dr. Peter Hohenberger, of the University of Heidelberg, in Mannheim, Germany, said in an accompanying comment that more research is needed.

"There are so many unknowns that this trial might not be able to provide a definitive treatment decision," he wrote. "To refine the indication for adjuvant treatment remains the big task for future studies."

More information

The American Cancer Society has more about GIST.



-- Robert Preidt



SOURCE: The Lancet, news release, March 18, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
2. Prescription Copay Assistance for Patients taking Gleevec or Tasigna for Philadelphia chromosome-positive Chronic Myelogenous Leukemia (Ph+ CML)
3. Cancer Drug Gleevec Could Fight Stroke
4. Cancer Drug Gleevec Linked to Muscle Damage
5. Protein predicts Gleevec resistance in gastrointestinal tumors
6. Gleevec Pushes Advanced Melanoma Into Remission
7. Gleevec May Disrupt Ovarian Function
8. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
9. Gleevec, the targeted cancer pill, delivers more good news to patients
10. Cell pathway on overdrive prevents cancer response to dietary restriction
11. New surgical implant tested at U-Iowa prevents total blindness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gleevec Prevents Return of Intestinal Cancer, Study Confirms
(Date:4/27/2017)... ... 27, 2017 , ... Healthcare companies are trying to meet talent shortages and ... healthcare executive resume. , “If you’re a healthcare executive open to new opportunities this ... it’s as ready as you are for a new job search. I’ve heard from ...
(Date:4/27/2017)... ... 27, 2017 , ... The American Brain Foundation last night ... Neurology Award (PLINA). The couple joins a prestigious list of past PLINA winners, ... actor Michael J. Fox and former U.S. Attorney General Janet Reno. , Smith ...
(Date:4/27/2017)... ... April 27, 2017 , ... SyncDog, Inc. ... at MobileIron Live! 2017 in Santa Clara, California. Each year, MobileIron ... approach to helping organizations maximize the benefits of mobility in their operations securely. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its kind, Swissx ... and more potent than the market has seen before. Swissx uses proprietary strains of ... a patented chromatography process for extraction, to produce its CBD oil--maximizing its benefits for ...
(Date:4/27/2017)... CA (PRWEB) , ... April 27, 2017 , ... Plastic ... MD , have been asked to present at the upcoming Aesthetic Meeting. Held in ... April 27-May 2. Drs. Furnas and Canales will lend their expertise to the Premier ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/18/2017)... 2017  Cardinal Health (NYSE: CAH ) ... earnings per share (EPS) guidance and providing a preliminary ... conjunction with this morning,s announcement of the planned acquisition ... Insufficiency businesses. Cardinal Health now believes that ... at the bottom of its previous guidance range of ...
(Date:4/18/2017)... April 18, 2017  Astute Medical, Inc., developer of ... to be presented at the 2017 National Kidney Foundation ... and continues through April 22. Physicians will present data ... to assess risk for acute kidney injury (AKI) during ... (ADHF). Elevated levels of TIMP-2 and ...
Breaking Medicine Technology: